TY - JOUR
T1 - Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma
T2 - propensity score analysis
AU - Kawamura, Koji
AU - Ikeda, Takashi
AU - Hagiwara, Shotaro
AU - Mori, Takehiko
AU - Shinagawa, Atsushi
AU - Nishiwaki, Kaichi
AU - Ohashi, Kazuteru
AU - Kubonishi, Shiro
AU - Fukuda, Takahiro
AU - Ito, Toshiro
AU - Tomita, Naoto
AU - Ichinohe, Tatsuo
AU - Kato, Koji
AU - Morishima, Yasuo
AU - Atsuta, Yoshiko
AU - Sunami, Kazutaka
AU - Kanda, Yoshinobu
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Abstract: Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n = 676) and auto/allo-HCT (n = 89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5% for the tandem auto-HCT group and 54.4% for the tandem auto/allo-HCT group (p = 0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.
AB - Abstract: Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n = 676) and auto/allo-HCT (n = 89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5% for the tandem auto-HCT group and 54.4% for the tandem auto/allo-HCT group (p = 0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.
UR - http://www.scopus.com/inward/record.url?scp=84961218189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961218189&partnerID=8YFLogxK
U2 - 10.3109/10428194.2016.1154958
DO - 10.3109/10428194.2016.1154958
M3 - Article
C2 - 26961137
AN - SCOPUS:84961218189
SN - 1042-8194
VL - 57
SP - 2077
EP - 2083
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -
